TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007
June 27 2018 - 4:01PM
REGULATED INFORMATIONPRESS
RELEASE
Transparency notification pursuant to Article
14 of the Law of May 2, 2007
Leuven (Belgium) - June 27, 2018, 22:00h
CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix")
announced today that it received a transparency notification
pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding
the publication of major holdings in issuers whose securities are
admitted to trading on a regulated market and including various
provisions.
Summary of the notification
On June 22, 2018, TiGenix received a
transparency notification from Sand Grove Capital Management LLP,
following the disposal of voting securities or voting rights on
June 6, 2018, after which Sand Grove Capital Management LLP
downward crossed the lowest threshold (3%) of total voting rights
of TiGenix.
Content of the notification
Date of the notification: June 21, 2018.
Reason of the notification: acquisition or
disposal of voting securities or voting rights / downward crossing
of the lowest threshold.
Person subject to the notification requirement:
Sand Grove Capital Management LLP (with address at 4th floor, 35
Dover Street, London W1S 4NQ), who is a person that notifies
alone.
Date on which the threshold was crossed: June 6,
2018.
Threshold that was crossed: 3%.
Denominator: 296,067,856.
Details of the notification: Following the
disposal of voting securities or voting rights, the number of
voting rights was as follows: Sand Grove Capital Management LLP
held 0 voting securities (0% of the total number of voting
rights).
Chain of controlled undertakings through which
the holding is effectively held: Sand Grove Capital Management LLP
is not a controlled entity.
Additional information: Sand Grove Capital
Management LLP acts as the investment manager for the Sand Grove
Opportunities Master Fund Ltd and the Sand Grove Tactical Fund LP.
Sand Grove Capital Management LLP can exercise voting rights at its
discretion without any instruction from its clients.
This press release and the above-mentioned transparency
notification can be consulted on our website:
- press release:
http://tigenix.com/news-media/press-releases
- notification:
http://tigenix.com/investors/share-information/shareholder-overview
For more information:
TiGenixClaudia JiménezSenior Director Investor
Relations and CommunicationsTel: +34918049264
Claudia.jimenez@tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels and NASDAQ: TIG)
is an advanced biopharmaceutical company developing novel therapies
for serious medical conditions by exploiting the anti-inflammatory
properties of allogeneic, or donor-derived, stem cells.
TiGenix lead product, Alofisel
(darvadstrocel), previously Cx601, received European Commission
(EC) approval for the treatment of complex perianal fistulas in
adult patients with non-active/mildly active luminal Crohn's
disease, when fistulas have shown an inadequate response to at
least one conventional or biologic therapy. A global Phase III
trial intended to support a future U.S. Biologic License
Application (BLA) started in 2017. TiGenix has entered into a
licensing agreement with Takeda, a global pharmaceutical company
active in gastroenterology, under which Takeda acquired the
exclusive right to develop and commercialize Alofisel for complex
perianal fistulas outside the U.S. TiGenix' second adipose-derived
product, Cx611, is undergoing a Phase I/II trial in severe sepsis -
a major cause of mortality in the developed world. TiGenix is
headquartered in Leuven (Belgium) and has operations in Madrid
(Spain) and Cambridge, MA (USA). For more information, please visit
http://www.tigenix.com.
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jul 2023 to Jul 2024